Replies to post #238873 on Biotech Values

[DewDiligence]

ICPT addendum:

$ICPT will reanalyze the biopsy dataset from REGENERATE using 2 independent pathologists plus a 3rd as a tiebreaker when needed. Doesn't exactly strike me as a game-changer.

— Roy Friedman (@DewDiligence) July 29, 2021

[DewDiligence]

ICPT does some financial engineering, but it’s not going to turn Ocaliva into an approvable drug for NASH:

https://www.globenewswire.com/news-release/2021/08/11/2278443/23024/en/Intercept-Pharmaceuticals-Announces-Convertible-Notes-Exchange-New-Issuance-and-Stock-Repurchase.html